Role of PAI-1 in hepatic steatosis and dyslipidemia
Abstract Plasminogen activator inhibitor 1 (PAI-1) is a functional biomarker of the metabolic syndrome. Previous studies have demonstrated that PAI-1 is a mechanistic contributor to several elements of the syndrome, including obesity, hypertension and insulin resistance. Here we show that PAI-1 is a...
Main Authors: | Joshua A. Levine, Carlota Oleaga, Mesut Eren, Ansel P. Amaral, Meng Shang, Elizabeth Lux, Sadiya S. Khan, Sanjiv J. Shah, Yasuhiro Omura, Nathalie Pamir, Joshua Hay, Grant Barish, Toshio Miyata, Hagai Tavori, Sergio Fazio, Douglas E. Vaughan |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-01-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-020-79948-x |
Similar Items
-
Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice
by: Anne S. Henkel, et al.
Published: (2018-12-01) -
Clinical and laboratory characteristics associated with dyslipidemia and liver steatosis in chronic HBV carriers
by: Angélica Luciana Nau, et al.
Published: (2014-04-01) -
Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL[S]
by: Hagai Tavori, et al.
Published: (2015-03-01) -
Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR −/− mice
by: Ganesan Murali, et al.
Published: (2012-10-01) -
Blackcurrant (<i>Ribes nigrum</i>) Extract Prevents Dyslipidemia and Hepatic Steatosis in Ovariectomized Rats
by: Naoki Nanashima, et al.
Published: (2020-05-01)